FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
Jaleh Fallah(United States Food and Drug Administration), Paul G. Kluetz(United States Food and Drug Administration), Haley Gittleman(University of California San Diego), Min Wang(Center for Drug Evaluation and Research), Daniel L. Suzman(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), William F. Pierce(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Laleh Amiri‐Kordestani(United States Food and Drug Administration), Anthony F. Fotenos(Center for Drug Evaluation and Research), Sundeep Agrawal(Center for Drug Evaluation and Research), Sriram Subramaniam(Center for Drug Evaluation and Research), Kelly Chiang(Center for Drug Evaluation and Research), Tiffany K. Ricks(United States Food and Drug Administration), Wei Chen(Center for Drug Evaluation and Research), Mallorie H. Fiero(Center for Drug Evaluation and Research), Christy S. John(Center for Drug Evaluation and Research), Gang Niu(National Institutes of Health), Amna Ibrahim(Beni-Suef University)
Cited by 236
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k